Last updated: September 5, 2026
Bendroflumethiazide and nadolol are mature cardiovascular medicines with limited remaining intellectual-property value. Nadolol has a continuing generic market in the United States and other jurisdictions. Bendroflumethiazide has a smaller commercial footprint, while the fixed-dose combination nadolol/bendroflumethiazide, historically marketed as Corzide, has limited current market visibility. Neither product has a credible biologic or biosimilar exposure. Financial performance is driven by generic pricing, manufacturing continuity, wholesaler purchasing, and supply concentration rather than patent exclusivity.
What are bendroflumethiazide and nadolol used for?
Nadolol is a nonselective beta-adrenergic blocker approved for hypertension and angina pectoris. Bendroflumethiazide is a thiazide diuretic used to treat hypertension and edema. The combination lowers blood pressure through complementary mechanisms: beta blockade reduces cardiac workload and renin activity, while the diuretic increases sodium and water excretion.
| Product |
Active ingredient |
Principal use |
Commercial status |
| Nadolol |
Nadolol |
Hypertension, angina |
Mature generic product |
| Bendroflumethiazide |
Bendroflumethiazide |
Hypertension, edema |
Niche, mature product |
| Corzide and generic equivalents |
Nadolol plus bendroflumethiazide |
Hypertension |
Limited and potentially discontinued in some markets |
The fixed-dose combination was historically marketed in strengths including 40 mg/5 mg, 80 mg/5 mg, 40 mg/10 mg, and 80 mg/10 mg, depending on jurisdiction and product availability. U.S. product labeling identifies the combination as nadolol and bendroflumethiazide tablets. [1]
When do bendroflumethiazide and nadolol lose exclusivity?
Both active ingredients lost meaningful exclusivity decades ago. The products originated in the era before modern pharmaceutical patent portfolios became central to lifecycle management. Any original composition-of-matter or early formulation patents would have expired long before the current generic market.
| Exclusivity category |
Nadolol |
Bendroflumethiazide |
Nadolol/bendroflumethiazide |
| New chemical entity exclusivity |
Expired |
Expired |
Not applicable |
| Original composition patent protection |
Expired |
Expired |
Expired or not commercially material |
| Current regulatory exclusivity |
None identified as commercially material |
None identified as commercially material |
None identified as commercially material |
| Biosimilar exclusivity |
Not applicable |
Not applicable |
Not applicable |
| Generic competition |
Established |
Established or limited by market |
Limited market participation |
The commercial question is therefore not when the products lose exclusivity. They already operate in a post-exclusivity environment. The relevant questions are whether a supplier can obtain regulatory approval, maintain reliable manufacturing, and sell at a price that supports production.
What is the FDA regulatory status and Orange Book position?
Nadolol has long-standing FDA approval as an oral tablet. The fixed-dose combination has also been approved historically as an oral tablet. FDA approval records and product labeling identify hypertension and related cardiovascular indications, but current commercial availability can differ from historical approval status. [1][2]
The Orange Book is relevant primarily for confirming listed patents and exclusivity associated with approved reference products. For these mature products, the commercial landscape is dominated by abbreviated new drug applications and generic labeling rather than active patent litigation. FDA’s Orange Book framework does not itself guarantee that a listed product remains commercially available or that every approved strength has active market supply. [3]
What patents protect nadolol?
No commercially significant, unexpired composition-of-matter protection is expected to remain for nadolol. Any residual patent value would most likely arise from a particular formulation, manufacturing process, or product-specific improvement. Such rights would need to be assessed patent by patent in the relevant jurisdiction.
For ordinary immediate-release nadolol tablets, the principal barrier is regulatory and operational. A prospective entrant must demonstrate pharmaceutical equivalence, bioequivalence, manufacturing compliance, and stability. Patent protection is not the central barrier.
What formulations are protected by patents?
The principal commercially relevant formulations are immediate-release oral tablets. There is no major current market for a patented extended-release or specialty-delivery nadolol product comparable to protected long-acting cardiovascular formulations.
For bendroflumethiazide, the same conclusion applies. The product is generally supplied as an oral tablet. The fixed-dose combination may create product-specific regulatory requirements, but the combination does not create a durable modern patent moat.
How many companies are competing in the nadolol market?
The nadolol market is a mature generic segment with competition varying by country, strength, and supplier. U.S. availability has historically included the reference brand Corgard and generic manufacturers. Generic supply can be more concentrated than the number of approved manufacturers suggests because some approved companies do not actively market every strength.
The practical competitive structure has four layers:
- Reference-brand or authorized-generic supply.
- Large generic manufacturers with national distribution.
- Smaller suppliers focused on selected strengths or institutional contracts.
- Wholesalers and pharmacies managing intermittent availability.
Nadolol is less interchangeable from a commercial perspective than many high-volume antihypertensives because demand is smaller, the product is older, and manufacturers may rationalize low-volume strengths. That can reduce active competition despite the absence of patent protection.
What is the financial trajectory for nadolol?
Nadolol has a low-growth, mature-generic financial profile. Unit demand is likely stable or declining over the long term because physicians have access to newer beta blockers, selective beta blockers, calcium-channel blockers, renin-angiotensin system therapies, and fixed-dose combination products.
Revenue is influenced by:
- Prescription persistence among patients stabilized on nadolol.
- Continued use in hypertension and angina.
- Availability of alternative beta blockers.
- Generic price compression.
- Shortages or discontinuations among smaller suppliers.
- Reimbursement treatment and pharmacy substitution.
- Institutional purchasing contracts.
The revenue trajectory is therefore best characterized as low-value and defensive rather than expansionary. A supplier with dependable inventory can achieve temporary price improvement during shortage conditions, but that pricing power is fragile. New entry can restore competition when manufacturing capacity returns.
No reliable public source establishes a current, standalone global revenue figure for nadolol across all manufacturers. Generic companies typically report revenue at the portfolio or business-segment level rather than disclosing sales for individual mature molecules. The absence of a transparent molecule-level revenue figure limits precise valuation, but the market structure indicates a small product opportunity relative to major cardiovascular generics.
What is the financial trajectory for bendroflumethiazide?
Bendroflumethiazide has a smaller and more specialized commercial base than nadolol. Thiazide therapy remains clinically relevant, but bendroflumethiazide competes with hydrochlorothiazide, chlorthalidone, indapamide, and combination antihypertensive products.
Its financial profile has three characteristics:
- Low absolute market value.
- Limited brand-driven pricing power.
- Greater sensitivity to supplier withdrawals and manufacturing economics.
Bendroflumethiazide may retain value as an ingredient in a fixed-dose combination where prescribers and patients are stable on the product. That value is different from growth value. It depends on continuity of supply and the persistence of the installed patient base.
The ingredient is unlikely to support major standalone investment in new clinical trials, specialty delivery, or broad commercial promotion. The stronger business case would be a low-cost regulatory and manufacturing platform serving an underserved niche.
What patent litigation affects bendroflumethiazide and nadolol?
No major current U.S. patent litigation is commercially associated with nadolol or bendroflumethiazide. The products do not present the litigation profile seen with recently approved small molecules that have active Orange Book patents, Paragraph IV challenges, and launch-at-risk disputes.
Are there Paragraph IV challenges?
Paragraph IV litigation is not expected to be a material current market driver for these products. The relevant patents are old, and generic entry occurred long ago. Any new Paragraph IV filing would require a currently listed, unexpired patent connected to an approved reference product. That is not the normal commercial structure for mature immediate-release nadolol or bendroflumethiazide products.
Are settlement agreements affecting generic entry?
No high-value, market-defining settlement agreement is publicly associated with current generic entry for these medicines. Any historical settlement would have limited relevance unless it imposed an unexpired launch restriction, which is unlikely for products of this age.
What generic entry risks exist for the combination product?
The primary risks are commercial rather than legal.
| Risk |
Effect on market |
| Low prescription volume |
Limits manufacturer interest |
| Multiple tablet strengths |
Raises inventory and regulatory costs |
| Supplier discontinuation |
Can produce temporary shortages |
| Generic price erosion |
Compresses gross margin |
| Alternative antihypertensives |
Reduces new-patient demand |
| Fixed-dose combination complexity |
Makes supply less flexible than single-ingredient tablets |
| Clinical substitution |
May shift patients to other beta blockers or diuretics |
A new generic entrant could obtain market share without confronting a significant patent barrier. The principal challenge would be achieving sufficient scale. A manufacturer would need to determine whether the combination’s sales justify separate production, packaging, quality control, pharmacovigilance, and distribution costs.
How does nadolol compare with competing beta blockers?
| Attribute |
Nadolol |
Metoprolol |
Propranolol |
Atenolol |
| Beta selectivity |
Nonselective |
Predominantly beta-1 selective |
Nonselective |
Beta-1 selective |
| Common formulations |
Immediate-release tablet |
Immediate- and extended-release |
Multiple oral and injectable forms |
Oral tablet |
| Generic competition |
Established |
Very broad |
Broad |
Broad |
| Market scale |
Smaller |
Larger |
Larger and diversified |
Mature |
| Differentiation |
Long half-life and established use |
Broad cardiovascular use |
Broad cardiovascular and neurologic use |
Low-cost hypertension therapy |
| Commercial outlook |
Stable to declining |
More resilient |
Diversified |
Mature and price-sensitive |
Nadolol’s long half-life can support once-daily dosing, but it does not create meaningful exclusivity. Metoprolol has a broader clinical and commercial base, while propranolol benefits from uses beyond routine hypertension. These factors give competing beta blockers greater portfolio value.
How does bendroflumethiazide compare with other diuretics?
Hydrochlorothiazide has much broader U.S. prescribing exposure and is widely included in fixed-dose combinations. Chlorthalidone and indapamide have clinical positioning in hypertension management and may be selected for longer duration or specific guideline preferences.
Bendroflumethiazide’s competitive weakness is not a lack of pharmacologic relevance. It is the limited scale of its commercial ecosystem. Fewer high-volume combinations, fewer active manufacturers, and lower prescribing visibility reduce its ability to support premium pricing.
What licensing deals or manufacturing barriers matter?
No major recent licensing transaction is required to explain the market position of these products. Licensing value would most likely involve:
- Transfer of an approved generic application.
- Contract manufacturing.
- Authorized-generic distribution.
- Regional commercialization rights.
- Acquisition of a niche cardiovascular portfolio.
Manufacturing barriers are moderate. The active ingredients are established small molecules, and the dosage forms are conventional tablets. The harder problems are batch economics, supplier qualification, stability data, packaging, and maintaining multiple strengths at low volumes.
Geographic coverage also matters. A product can be commercially viable in one country while unavailable in another because of local registration, reimbursement, distributor, or supply decisions. U.S., European, Canadian, and emerging-market status should therefore be analyzed separately rather than treated as a single global market.
What is the generic launch outlook?
The most likely launch scenario is limited-entry generic supply rather than a major competitive wave. A new manufacturer could enter without substantial patent risk, but the addressable market may be too small to attract several new suppliers.
The likely outcomes are:
- Nadolol: continued generic availability with periodic supplier changes and price pressure.
- Bendroflumethiazide: niche supply with greater discontinuation sensitivity.
- Combination product: selective availability, potentially dependent on one or a few suppliers.
- Branded products: limited pricing power unless supply shortages create temporary differentiation.
Key Takeaways
- Nadolol and bendroflumethiazide are mature, off-patent cardiovascular medicines.
- Nadolol has the larger and more durable generic market.
- Bendroflumethiazide is a smaller niche product facing competition from hydrochlorothiazide, chlorthalidone, and indapamide.
- The nadolol/bendroflumethiazide combination has limited current commercial momentum.
- Patent litigation, Paragraph IV challenges, biosimilar risk, and settlement restrictions are not the primary market issues.
- Financial performance depends on generic volume, price erosion, manufacturing continuity, and supply concentration.
- A new entrant would face low patent risk but uncertain return on investment.
- The strongest opportunity is a low-cost, reliable supply strategy rather than a premium-price or innovation-led strategy.
FAQs
Is nadolol still commercially available?
Yes. Nadolol remains available as a generic prescription beta blocker in several markets, although individual strengths and suppliers may vary.
Is bendroflumethiazide the same as hydrochlorothiazide?
No. Both are thiazide diuretics, but they are different active ingredients with different historical prescribing patterns, formulations, and market availability.
Is Corzide still sold in the United States?
Historical U.S. labeling identifies Corzide as nadolol plus bendroflumethiazide. Current commercial availability may be limited or dependent on generic supply and distributor activity. [1]
Can a generic company launch nadolol without a Paragraph IV dispute?
Yes, if no enforceable, unexpired patent blocks the proposed product. For mature immediate-release nadolol, regulatory approval and manufacturing economics are generally more important than patent litigation.
Does nadolol have biosimilar competition?
No. Nadolol is a chemically synthesized small molecule, so it is regulated through generic-drug pathways rather than biologic biosimilar pathways.
References
- DailyMed. (n.d.). Nadolol and bendroflumethiazide tablets prescribing information. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. U.S. Department of Health and Human Services.
